Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV-infected HAART-suppressed individuals with poor CD4 T-cell recovery-Reference-Cited by-同舟云学术

Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV-infected HAART-suppressed individuals with poor CD4 T-cell recovery

Published:2012-11-28 Issue:18 Volume:26 Page:2285-2293
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:

Author:

Massanella Marta,Negredo Eugènia,Puig Jordi,Puertas Maria C.,Buzón Maria J.,Pérez-Álvarez Núria,Carrillo Jorge,Clotet Bonaventura,Martínez-Picado Javier,Blanco Julià

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference31 articles.

1. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease.;Piketty;AIDS,1998

2. Mechanisms involved in the low-level regeneration of CD4 cells in HIV-1-infected patients receiving highly active antiretroviral therapy who have prolonged undetectable plasma viral loads.;Benveniste;J Infect Dis,2005

3. CD4 T-cell hyperactivation and susceptibility to cell death determine poor CD4 T-cell recovery during suppressive HAART.;Massanella;AIDS,2010

4. The absence of CD4 T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options.;Gazzola;Clin Infect Dis,2009

5. HIV disease progression despite suppression of viral replication is associated with exhaustion of lymphopoiesis.;Sauce;Blood,2011

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Relationship between Modern ART Regimens and Immunosenescence Markers in Patients with Chronic HIV Infection;Viruses;2024-07-26

2. Transgender Women With Suppressed Testosterone Display Lower Burden of Coronary Disease Than Matched Cisgender Men;Journal of the Endocrine Society;2024-06-27

3. Long-term safety and impact of immune recovery in heavily treatment-experienced adults receiving fostemsavir for up to 5 years in the phase 3 BRIGHTE study;Frontiers in Immunology;2024-05-28

4. Genetic, virological, infectious, and pharmacological risk factors for CD4<sup>+</sup> T-cell regeneration failure in HIV-infected subjects receiving ART;HIV Infection and Immunosuppressive Disorders;2023-10-21

5. Immunological inefficiency of art in HIV-infected patients;HIV Infection and Immunosuppressive Disorders;2023-07-20